FDA-approved Sexual & reproductive

Lutetium Lu-177 vipivotide tetraxetan

Lutetium Lu-177 vipivotide tetraxetan is a PSMA-targeted radioligand. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Lutetium Lu-177 vipivotide tetraxetan has an FDA-approved product on the U.S. market, marketed as Pluvicto under application NDA215833.

The current label is held by Novartis Pharmaceuticals Corporation.

From the FDA label

What Lutetium Lu-177 vipivotide tetraxetan is approved to treat

is a radioligand therapeutic agent indicated: Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Lutetium Lu-177 vipivotide tetraxetan, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Lutetium Lu-177 vipivotide tetraxetan. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides